Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter study designed to evaluate the progression free survival of
the SOL group (S-1, Leucovorin, and Oxaliplatin) compared with the mFOLFOX6 group (5-FU, l-LV
and Oxaliplatin) as first-line treatment of patients with metastatic colorectal cancer.